GleamWall
中文EN

ODTX Odyssey Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1882782 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets14.2%
Debt / equity0.00x
Current ratio12.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$0$0$0$99,000$959,000$1.92M
R&D expense$42.12M$36.23M$32.32M$26.32M$30.23M$38.77M
SG&A expense$11.24M$10.51M$7.35M$10.16M$13.22M$7.95M
Operating income-$56.67M-$55.47M-$39.78M-$38.25M-$41.92M-$39.16M
Interest expense$12,000$20,000$10,000$1,000$2,000$2,000
Pretax income-$53.01M-$52.80M-$38.20M-$35.52M-$41.20M-$38.30M
Income tax$49,000-$8,000$63,000-$56,000$30,000$140,000
Net income-$53.06M-$52.79M-$38.26M-$35.46M-$41.23M-$38.44M
EBITDA-$55.77M-$54.57M-$38.61M-$37.15M-$40.82M-$37.86M
EPS (basic)-1.10-1.74-6.77-7.78-29.54-39.37
EPS (diluted)-1.10-1.74-6.77-7.78-29.54-39.37
Weighted avg. shares (diluted)48.02M30.28M5.66M4.56M1.40M976,146
Balance sheet
Cash & equivalents$80.64M$82.03M$35.72M$49.52M$163.00M$54.91M
Short-term investments$245.36M$228.54M$140.03M———
Receivables$0$0$0$0$0$0
Current assets$337.80M$321.46M$185.10M———
PP&E, net$4.63M$4.88M$6.56M———
Goodwill$14.12M$14.10M$14.07M———
Intangibles$0$86,000$160,000———
Total assets$438.10M$483.85M$229.07M———
Current liabilities$26.10M$28.30M$22.21M———
Total liabilities$62.33M$62.63M$49.21M———
Shareholders' equity$375.77M$421.22M-$523.69M-$460.80M-$436.36M-$417.17M
Shares outstanding47.94M47.89M2.48M———
Cash flow statement
Operating cash flow-$41.54M-$34.51M-$41.03M-$31.26M-$34.26M-$38.62M
Capital expenditure$504,000$186,000$148,000$48,000$29,000$927,000
Free cash flow-$42.05M-$34.69M-$41.18M-$31.30M-$34.29M-$39.55M
Investing cash flow$43.29M-$211.44M$34.80M-$172.90M$23.30M$34.13M
Financing cash flow-$3.18M$292.16M$484,000$90.78M$118.72M$200,000
Depreciation & amortization$900,000$900,000$1.17M$1.10M$1.10M$1.30M
Stock-based compensation$7.94M$5.67M$2.59M$4.89M$3.70M$2.99M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.